Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): A randomised phase 3 trial

Jean Yves Blay, Lin Shen, Yoon Koo Kang, Piotr Rutkowski, Shukui Qin, Dmitry Nosov, Desen Wan, Jonathan Trent, Vichien Srimuninnimit, Zsuzsanna Pápai, Axel Le Cesne, Steven Novick, Lilia Taningco, Shuyuan Mo, Steven Green, Peter Reichardt, George D. Demetri

Research output: Contribution to journalArticle

46 Scopus citations

Fingerprint Dive into the research topics of 'Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): A randomised phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences